Aridis Pharmaceuticals Analyst Ratings
Aridis Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/20/2021 | 850% | HC Wainwright & Co. | $11 → $19 | Maintains | Buy |
| 05/15/2020 | 450% | HC Wainwright & Co. | $7 → $11 | Reiterates | → Buy |
| 02/19/2020 | 800% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
| 12/30/2019 | 250% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 09/10/2018 | 1900% | Northcoast Research | → $40 | Initiates Coverage On | → Outperform |
| 09/10/2018 | 1050% | Laidlaw & Co. | → $23 | Initiates Coverage On | → Buy |
| 09/10/2018 | 1150% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变化 | 上一页/当前额定值 |
|---|---|---|---|---|---|
| 08/16/2022 | — | 马克西姆集团 | 降级 | 买入 → 持有 | |
| 2021 年 7 月 20 日 | 850% | HC Wainwright & Co. | 11 美元 → 19 美元 | 维护 | 买 |
| 05/15/2020 | 450% | HC Wainwright & Co. | 7 美元 → 11 美元 | 重申 | → 购买 |
| 2020 年 2 月 19 日 | 800% | 罗斯资本 | → 18 美元 | 开启覆盖范围 | → 购买 |
| 2019 年 12 月 30 日 | 250% | HC Wainwright & Co. | → 7 美元 | 开启覆盖范围 | → 购买 |
| 2018 年 10 月 9 日 | 1900% | 北海岸研究 | → 40 美元 | 开启覆盖范围 | → 跑赢大盘 |
| 2018 年 10 月 9 日 | 1050% | Laidlaw & Co. | → 23 美元 | 开启覆盖范围 | → 购买 |
| 2018 年 10 月 9 日 | 1150% | 坎托·菲茨杰拉德 | → 25 美元 | 开启覆盖范围 | → 超重 |
Aridis Pharmaceuticals Questions & Answers
Aridis Pharmicals 问题
The latest price target for Aridis Pharmaceuticals (NASDAQ: ARDS) was reported by Maxim Group on August 16, 2022. The analyst firm set a price target for $0.00 expecting ARDS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
Maxim集团于2022年8月16日公布了阿里迪斯制药（纳斯达克股票代码：ARDS）的最新目标股价。该分析公司将目标股价定为0.00美元，预计ARDS将在12个月内降至-100.00％（下行幅度可能为-100.00％）。去年有1家分析公司公布了评级。
The latest analyst rating for Aridis Pharmaceuticals (NASDAQ: ARDS) was provided by Maxim Group, and Aridis Pharmaceuticals downgraded their hold rating.
Aridis Pharmicals（纳斯达克股票代码：ARDS）的最新分析师评级由Maxim集团提供，Aridis Pharmicals下调了持有评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aridis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aridis Pharmaceuticals was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表、与Aridis Pharmicals的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Aridis Pharmicals的最后一次评级是在2022年8月16日提交的，因此您应该预计下一个评级将在2023年8月16日左右公布。
While ratings are subjective and will change, the latest Aridis Pharmaceuticals (ARDS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Aridis Pharmaceuticals (ARDS) is trading at is $2.00, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Aridis Pharmicals（ARDS）评级被下调，目标股价为0.00美元至0.00美元。Aridis Pharmicals（ARDS）目前的交易价格为2.00美元，超出了分析师的预期区间。